Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review

Advances in Therapy

Volumn 33, Issue 7, 2016, Pages 1094-1104

  Ansaldi, Filippo ^a,b   Trucchi, Cecilia ^a   Alicino, Cristiano ^a   Paganino, Chiara ^a   Orsi, Andrea ^a,b   Icardi, Giancarlo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Herpes zoster; Infectious diseases; Post herpetic neuralgia; Shingles; Vaccine; Vaccine effectiveness; Vaccine safety

Indexed keywords

VARICELLA ZOSTER VACCINE;

ALOPECIA; ARTHRITIS; CLINICAL PRACTICE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HUMAN; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MULTIPLE SCLEROSIS; NONHUMAN; OPTIC NEURITIS; POSTHERPETIC NEURALGIA; PREVENTIVE HEALTH SERVICE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VACCINATION; VARICELLA ZOSTER VIRUS; VASCULITIS; VIRUS REACTIVATION; AGE; EUROPE; NEURALGIA, POSTHERPETIC; PHASE 3 CLINICAL TRIAL (TOPIC);

AGE FACTORS; CLINICAL TRIALS, PHASE III AS TOPIC; EUROPE; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC;

EID: 84978080650     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0355-0     Document Type: Review

References (56)

1. Public Health Agency of Canada. Varicella-zoster virus. Pathogen safety data sheet—infectious substances 2012. http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/var-zo-eng.php. Accessed 22 Apr 2016.
2. Whitley RJ. Chapter 68: Herpesviruses. In: Baron S, editor. Medical microbiology. Galveston: University of Texas Medical Branch at Galveston; 1996.
3. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21–6.
4. Mori I, Nishiyama Y. Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol. 2005;15(6):393–406.
5. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369(3):255–63.
6. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–80.
7. Watson PN. Postherpetic neuralgia. BMJ Clin Evid. 2010;2010:519.
8. Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2006;37(1):73–80.
9. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61(2):203–7.
10. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin’s disease undergoing autologous bone marrow transplant. Bone Marrow Transplant. 1991;7(6):435–7.
11. Dunst J, Steil B, Furch S, Fach A, Bormann G, Marsch W. Herpes zoster in breast cancer patients after radiotherapy. Strahlenther Onkol. 2000;176(11):513–6.
12. Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991;18(Suppl A):317–29.
13. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4(1):108–15.
14. Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomark Prev. 2013;22(1):82–90.
15. Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: Time to reconsider current recommendations. Clin Infect Dis. 2014;59(7):920–2.
16. Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13(1):15–23.
17. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483–90.
18. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104(10):2524–33.
19. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis. 1990;49(8):630–3.
20. Ranganathan P. Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors. Ann Rheum Dis. 2013;72(5):e4.
21. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–8.
22. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-tnf-alpha agents. JAMA. 2009;301(7):737–44.
23. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013;65(6):854–61.
24. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370–5.
25. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
26. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731–6.
27. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.
28. Food and Drug Administration. News and events 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108659.htm. Accessed 22 Apr 2016.
29. European Medicines Agency. Zostavax 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000674/human_med_001185.jsp&mid=WC0b01ac058001d124. Accessed 22 Apr 2016.
30. Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR. 2011;60(44):1528.
31. Centers for Disease Control and Prevention. Shingles vaccination: what everyone should know 2016. http://www.cdc.gov/vaccines/vpd-vac/shingles/vacc-need-know.htm. Accessed 22 Apr 2016.
32. Centers for Disease Control and Prevention. Update on recommendations for use of herpes zoster vaccine. MMWR. 2014;63(33):729–31.
33. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.
34. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–8.
35. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.
36. Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
37. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872–5.
38. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.
39. Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, et al. Zoster vaccine and the risk of postherpetic neuralgia in patients who developed herpes zoster despite having received the zoster vaccine. J Infect Dis. 2015;212(8):1222–31.
40. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.
41. Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11(5):1157–64.
42. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.
43. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN, Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900–9.
44. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (acip). MMWR. 2008;57(Rr-5):1–30.
45. Maggi S, Gabutti G, Franco E, Bonanni P, Conversano M, Ferro A, et al. Preventing and managing herpes zoster: key actions to foster healthy aging. Aging Clin Exp Res. 2015;27(1):5–11.
46. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.
47. Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8(5):259–70.
48. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.
49. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.
50. Tseng HF, Tartof S, Harpaz R, Luo Y, Sy LS, Hetcher RC, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913–9.
51. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.
52. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.
53. Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, et al. Safety of Zostavax—a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.
54. Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: a case-control study of adverse events in a national database. J Drugs Dermatol. 2015;14(7):681–4.
55. ®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87(1):123–5.
56. Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865–73.